Ken Griffin
ATOS icon

Ken Griffin’s Atossa Therapeutics ATOS Stock Holding History

Ken Griffin’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,720
Closed -$50.6K – 12941
2025
Q4 		$50.6K Buy
5,720
+4,040
+240% +$51.1K ﹤0.01% 12029
2025
Q3 		$21.8K Buy
1,680
+833
+98% +$10.3K ﹤0.01% 12477
2025
Q2 		$10.5K Sell
847
-1,406
-62% -$16.8K ﹤0.01% 12196
2025
Q1 		$22.7K Buy
2,253
+860
+62% +$10.4K ﹤0.01% 13049
2024
Q4 		$19.7K Sell
1,393
-3,114
-69% -$60.8K ﹤0.01% 13190
2024
Q3 		$103K Buy
4,507
+1,667
+59% +$33.7K ﹤0.01% 11078
2024
Q2 		$50.7K Sell
2,840
-773
-21% -$17.1K ﹤0.01% 11742
2024
Q1 		$97.6K Buy
3,613
+2,253
+166% +$36.2K ﹤0.01% 11390
2023
Q4 		$18K Sell
1,360
-360
-21% -$3.88K ﹤0.01% 12713
2023
Q3 		$19K Sell
1,720
-2,053
-54% -$29.8K ﹤0.01% 12669
2023
Q2 		$71.3K Sell
3,773
-447
-11% -$5.42K ﹤0.01% 11372
2023
Q1 		$45.9K Sell
4,220
-2,253
-35% -$25.1K ﹤0.01% 12269
2022
Q4 		$51.3K Sell
6,473
-1,507
-19% -$17.3K ﹤0.01% 12103
2022
Q3 		$100K Buy
7,980
+60
+0.8% +$871 ﹤0.01% 11094
2022
Q2 		$129K Sell
7,920
-2,373
-23% -$37.4K ﹤0.01% 11142
2022
Q1 		$193K Sell
10,293
-5,220
-34% -$106K ﹤0.01% 11582
2021
Q4 		$372K Sell
15,513
-22,647
-59% -$829K ﹤0.01% 10418
2021
Q3 		$1.87M Sell
38,160
-23,213
-38% -$1.35M ﹤0.01% 6539
2021
Q2 		$5.82M Buy
61,373
+32,740
+114% +$1.73M ﹤0.01% 4111
2021
Q1 		$906K Buy
28,633
+25,140
+720% +$919K ﹤0.01% 8364
2020
Q4 		$50K Buy
3,493
+1,833
+110% +$42.4K ﹤0.01% 10565
2020
Q3 		$60K Buy
1,660
+500
+43% +$24K ﹤0.01% 9532
2020
Q2 		$66K Buy
+1,160
New +$41.1K ﹤0.01% 9184
2020
Q1 		– Sell
-733
Closed -$17K – 9559
2019
Q4 		$17K Sell
733
-87
-11% -$2.04K ﹤0.01% 8958
2019
Q3 		$24K Sell
820
-313
-28% -$9.91K ﹤0.01% 8894
2019
Q2 		$43K Buy
+1,133
New +$45.4K ﹤0.01% 8768

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ken Griffin's ATOS Position: Q1 2026 in Review

Ken Griffin sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 43,208 shares — an estimated $382K sold.

Ken Griffin first reported a position in ATOS in Q3 2014 and held it in 25 quarters. The position peaked at $3.33M in Q3 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Ken Griffin reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 43,208 Atossa Therapeutics shares in Q1 2026, an estimated $382K.
  • Ken Griffin first reported a position in Atossa Therapeutics in Q3 2014 and held it in 25 quarters.
  • Ken Griffin's Atossa Therapeutics position peaked at $3.33M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.